Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9806406 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL13513577 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL6087782 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL2397638 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL9806410 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL11435680 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL51731 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL9806415 | 1.00 | ALDH1A1 (0.46) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL51551 | 0.97 | ALDH1A1 (0.42) | ALDH1A1EPHX1SPHK1SPHK2TSHR | |
| SCHEMBL9011829 | 0.95 | ALDH1A1 (0.41) | ALDH1A1EPHX1SPHK1SPHK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015168771-A1 | CARDANOL GLYCIDYL ETHER DERIVATIVES | CENTRE DE TECHNOLOGIE MINERALE ET DE PLASTURGIE INC. (CA) | 2015-11-12 | — | — | WO | disclosed |
| CN-104725600-A | The optical epoxy resin composition and cured product thereof | NIPPON STEEL & SUMIKIN CHEM CO | 2015-06-24 | — | — | CN | disclosed |
| US-20120149768-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149768-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | ALDH1A1 3269/4885EPHX1 303/4885SPHK1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.